Similar articles

• Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men.

  Alibhai SM, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE, Paszat L. Alibhai SM, et al. J Urol. 2010 Sep;184(3):918-23. doi: 10.1016/j.juro.2010.04.068. J Urol. 2010. PMID: 20643458
• ACP Journal Club. Intermittent and continuous androgen deprivation did not differ for mortality after radiotherapy for prostate cancer.

  Stockler MR. Stockler MR. Ann Intern Med. 2013 Jan 15;158(2):JC9. doi: 10.7326/0003-4819-158-2-201301150-02009. Ann Intern Med. 2013. PMID: 23318343 No abstract available.
• Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.

  Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D, Hancock ML, Steiner MS. Smith MR, et al. J Urol. 2013 Jan;189(1 Suppl):S45-50. doi: 10.1016/j.juro.2012.11.016. J Urol. 2013. PMID: 23234631 Clinical Trial.
• Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.

  Kintzel PE, Chase SL, Schultz LM, O'Rourke TJ. Kintzel PE, et al. Pharmacotherapy. 2008 Dec;28(12):1511-22. doi: 10.1592/phco.28.12.1511. Pharmacotherapy. 2008. PMID: 19025432 Review.
• The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.

  Smith MR. Smith MR. Oncology (Williston Park). 2004 May;18(5 Suppl 3):21-5. Oncology (Williston Park). 2004. PMID: 15202584 Review.